

## **VentriPoint Diagnostics Files Management Discussion and Analysis, Audited Financial Results**

### ***Completion of Tetralogy of Fallot Database and Successful Demonstration of VentriPoint Diagnostic System Highlights of Management Discussion and Analysis***

SEATTLE, April 30, 2008 – VentriPoint Diagnostics (TSX: VPT) today announced that it has filed its management discussion and analysis (MD&A), as well as its audited financial results for the year ended Dec. 31, 2007, with the Canadian Securities Administrators through the SEDAR filing system.

#### Development Highlights

In its MD&A, VentriPoint describes development highlights such as the recent completion and validation of the accuracy of its tetralogy of fallot (TOF) specific database to support its Knowledge Based Reconstruction (KBR). Using the VentriPoint Diagnostic System, anatomical points identified on two dimensional images are referenced with this TOF database comprised of three dimensional reconstruction reference data from 110 patients' heart images, including 54 with TOF. Using KBR, the VentriPoint Diagnostic System automatically generates a three dimensional model of the right ventricle and provides volume and ejection fraction measurements that cardiologists can use to better monitor and evaluate heart status and the efficacy of treatments.

“As we describe in the MD&A, the completion of this database and the successful demonstration of an accurate three dimensional reconstruction by the VentriPoint Diagnostic System at our April board of directors meeting validates the substantial progress achieved in our efforts to commercialize the VentriPoint Diagnostic System,” said Joseph Ashley, CEO of VentriPoint Diagnostics. “We are aggressively pursuing the expansion and completion of the three other disease specific databases which we are planning to include with our scheduled

commercial launch of the VentriPoint Diagnostic System product offering in early 2009.”

### Financial Highlights

In its audited financial results, VentriPoint reported a consolidated net loss of \$1,396,759 for the year ended Dec. 31, 2007, or \$0.07 per share compared to a net loss of \$879,137, or \$0.15 per share for the year ended Dec. 31, 2006. The increase in net loss is attributed to planned expenditures to accelerate the development of the VentriPoint Diagnostic System.

For the year ended Dec. 31, 2007, research and development expenses totaled \$950,303, compared to \$614,031 for the year ended Dec. 31, 2006. The largest research and development expense for the year ended December 31, 2007 was payroll costs to build a highly qualified research and development team.

VentriPoint reported a foreign exchange gain of \$140,112 as the result of a change in the currency exchange rate used to translate Canadian monetary items into the US dollar between the financing transactions closed on Sept. 18, 2007, and the financial statement date, Dec. 31, 2007. Interest income was also reported in the amount of \$59,273 for the year ended Dec. 31, 2007, compared to \$0 for the year ended 2006.

On Sept. 18, 2007, VentriPoint Diagnostics completed three major integrated financing transactions that have significantly accelerated the development process. The Company converted \$400,000 (CDN) of Debentures into common shares and warrants; completed the acquisitions of all of the outstanding shares, warrants and options of VentriPoint by exchanging Diagnostics shares, warrants and options on a one to one basis; and closed a \$4,025,000 (CDN) private placement with Blackmont Capital Inc. acting as agent.

### **About VentriPoint Diagnostics**

VentriPoint creates diagnostic tools to monitor patients with heart disease – the number one cause of death in developed countries. By using images produced from existing medical imaging systems, the VentriPoint Diagnostic System generates critical heart measurements in a rapid and inexpensive manner not currently available. This breakthrough diagnostic tool is based upon technology received by VentriPoint through its technology license with the University of Washington. The VentriPoint Diagnostic System, together with its associated online service, is being developed for a variety of heart related disease states, including congenital heart disease.